MCETOTCHealthcare · Biotechnology

MultiCell Technologies, Inc.

$0.00+0.00%(+$0.00)

TickerSpark Score

46/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MCET research report →

52-Week Range50% of range

Low $0.00

Current $0.00

High $0.00

Companywww.multicelltech.com

MultiCell Technologies, Inc. , a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers.

CEO: W. Gerald Newmin
IPO: 2000
Employees: 2
HQ: Woonsocket, RI, US

Price Chart

+0.00% · this period

Valuation

Market Cap: $50.01K
P/E: -0.10
P/S: 1014.01
P/B: -0.31
EV/EBITDA: -0.10
Div Yield: 0.00%

Profitability

Gross Margin: 100.00%
Op Margin: -1465.60%
Net Margin: -770.65%
ROE: 164.07%
ROIC: 81.33%

Growth & Income

Revenue: $49.318 · 0.00%
Net Income: $-380.071 · 69.22%
EPS: $-0.00 · 83.33%
Op Income: $-722.807
FCF YoY: 13.01%

Performance & Tape

52W High: $0.00
52W Low: $0.00
50D MA: $0.00
200D MA: $0.00
Beta: -35.68
Avg Volume: 342.49K

Get TickerSpark's AI analysis on MCET

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime